Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID-19 patients with pre-existing comorbidities
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
The difficulty in predicting fatal outcomes in patients with coronavirus disease 2019 (COVID-19) impacts the general morbidity and mortality due to severe acute respiratory syndrome-coronavirus 2 infection, as it wears out the hospital services that care for these patients. Unfortunately, in several of the candidates for prognostic biomarkers proposed, the predictive power is compromised when patients have pre-existing comorbidities. A cohort of 147 patients hospitalized for severe COVID-19 was included in a descriptive, observational, single-center, and prospective study. Patients were recruited during the first COVID-19 pandemic wave (April-November 2020). Data were collected from the clinical history whereas immunophenotyping by multiparameter flow cytometry analysis allowed us to assess the expression of surface markers on peripheral leucocyte. Patients were grouped according to the outcome in survivors or non-survivors. The prognostic value of leucocyte, cytokines or HLA-DR, CD39, and CD73 was calculated. Hypertension and chronic renal failure but not obesity and diabetes were conditions more frequent among the deceased patient group. Mixed hypercytokinemia, including inflammatory (IL-6) and anti-inflammatory (IL-10) cytokines, was more evident in deceased patients. In the deceased patient group, lymphopenia with a higher neutrophil-lymphocyte ratio (NLR) value was present. HLA-DR expression and the percentage of CD39+ cells were higher than non-COVID-19 patients but remained similar despite the outcome. Receiver operating characteristic analysis and cutoff value of NLR (69.6%, 9.4), percentage NLR (pNLR; 71.1%, 13.6), and IL-6 (79.7%, 135.2 pg/mL). The expression of HLA-DR, CD39, and CD73, as many serum cytokines (other than IL-6) and chemokines levels do not show prognostic potential, were compared to NLR and pNLR values.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical and translational science - 16(2023), 12 vom: 05. Dez., Seite 2687-2699 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cts.13663 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363658394 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363658394 | ||
| 003 | DE-627 | ||
| 005 | 20240418232321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.13663 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM363658394 | ||
| 035 | |a (NLM)37873554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Madera-Sandoval, Ruth Lizzeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID-19 patients with pre-existing comorbidities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a The difficulty in predicting fatal outcomes in patients with coronavirus disease 2019 (COVID-19) impacts the general morbidity and mortality due to severe acute respiratory syndrome-coronavirus 2 infection, as it wears out the hospital services that care for these patients. Unfortunately, in several of the candidates for prognostic biomarkers proposed, the predictive power is compromised when patients have pre-existing comorbidities. A cohort of 147 patients hospitalized for severe COVID-19 was included in a descriptive, observational, single-center, and prospective study. Patients were recruited during the first COVID-19 pandemic wave (April-November 2020). Data were collected from the clinical history whereas immunophenotyping by multiparameter flow cytometry analysis allowed us to assess the expression of surface markers on peripheral leucocyte. Patients were grouped according to the outcome in survivors or non-survivors. The prognostic value of leucocyte, cytokines or HLA-DR, CD39, and CD73 was calculated. Hypertension and chronic renal failure but not obesity and diabetes were conditions more frequent among the deceased patient group. Mixed hypercytokinemia, including inflammatory (IL-6) and anti-inflammatory (IL-10) cytokines, was more evident in deceased patients. In the deceased patient group, lymphopenia with a higher neutrophil-lymphocyte ratio (NLR) value was present. HLA-DR expression and the percentage of CD39+ cells were higher than non-COVID-19 patients but remained similar despite the outcome. Receiver operating characteristic analysis and cutoff value of NLR (69.6%, 9.4), percentage NLR (pNLR; 71.1%, 13.6), and IL-6 (79.7%, 135.2 pg/mL). The expression of HLA-DR, CD39, and CD73, as many serum cytokines (other than IL-6) and chemokines levels do not show prognostic potential, were compared to NLR and pNLR values | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 700 | 1 | |a Cérbulo-Vázquez, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Arriaga-Pizano, Lourdes Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrera-Rivera, Graciela Libier |e verfasserin |4 aut | |
| 700 | 1 | |a Basilio-Gálvez, Edna |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda-Cruz, Patricia Esther |e verfasserin |4 aut | |
| 700 | 1 | |a García de la Rosa, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto-Chávez, Jessica Lashkmin |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero-Arredondo, Silvia Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz-Cruz, Alonso |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Hernández, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar-Ríos, María Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar-Ríos, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-Molina, Esli David |e verfasserin |4 aut | |
| 700 | 1 | |a De Lira-Barraza, Roberto Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Villanueva-Compean, Abel Humberto |e verfasserin |4 aut | |
| 700 | 1 | |a Esquivel-Pineda, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Montes de Oca, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Unzueta-Marta, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Flores-Padilla, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Anda-Garay, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Hurtado, Luis Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Calleja-Alarcón, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gutiérrez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Rosas, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifaz, Laura C |e verfasserin |4 aut | |
| 700 | 1 | |a Pelayo, Rosana |e verfasserin |4 aut | |
| 700 | 1 | |a Márquez-Márquez, Edna |e verfasserin |4 aut | |
| 700 | 1 | |a López-Macías, Constantino I I I Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ferat-Osorio, Eduardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 16(2023), 12 vom: 05. Dez., Seite 2687-2699 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:12 |g day:05 |g month:12 |g pages:2687-2699 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.13663 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 12 |b 05 |c 12 |h 2687-2699 | ||